DK3127917T3 - Fremgangsmåde til fremstilling af antistof gennem regulering af sukkerindhold i antistof - Google Patents

Fremgangsmåde til fremstilling af antistof gennem regulering af sukkerindhold i antistof Download PDF

Info

Publication number
DK3127917T3
DK3127917T3 DK15773537.4T DK15773537T DK3127917T3 DK 3127917 T3 DK3127917 T3 DK 3127917T3 DK 15773537 T DK15773537 T DK 15773537T DK 3127917 T3 DK3127917 T3 DK 3127917T3
Authority
DK
Denmark
Prior art keywords
antibody
regulating
procedure
production
sugar content
Prior art date
Application number
DK15773537.4T
Other languages
English (en)
Inventor
Jae Young Chang
Eun Ho Hwang
Yong Jin Kim
Won Kyum Kim
Sang Kyung Park
Jun Yong Park
Kyo Eun Ahn
Yong Ho Ahn
Ji Yong Yoon
Jung Woo Lee
Original Assignee
Prestige Biopharma Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prestige Biopharma Pte Ltd filed Critical Prestige Biopharma Pte Ltd
Application granted granted Critical
Publication of DK3127917T3 publication Critical patent/DK3127917T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK15773537.4T 2014-04-02 2015-04-02 Fremgangsmåde til fremstilling af antistof gennem regulering af sukkerindhold i antistof DK3127917T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020140039307A KR101660580B1 (ko) 2014-04-02 2014-04-02 항체의 당 함량 조절을 통한 항체의 제조 방법
PCT/KR2015/003310 WO2015152658A1 (ko) 2014-04-02 2015-04-02 항체의 당 함량 조절을 통한 항체의 제조 방법

Publications (1)

Publication Number Publication Date
DK3127917T3 true DK3127917T3 (da) 2021-09-20

Family

ID=54240880

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15773537.4T DK3127917T3 (da) 2014-04-02 2015-04-02 Fremgangsmåde til fremstilling af antistof gennem regulering af sukkerindhold i antistof

Country Status (9)

Country Link
US (1) US10808272B2 (da)
EP (1) EP3127917B1 (da)
JP (1) JP6389530B2 (da)
KR (1) KR101660580B1 (da)
CN (1) CN106459185B (da)
DK (1) DK3127917T3 (da)
ES (1) ES2893536T3 (da)
PT (1) PT3127917T (da)
WO (1) WO2015152658A1 (da)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202140776A (zh) * 2016-04-26 2021-11-01 美商美國泰福生技股份有限公司 細胞培養基
CN113015805A (zh) * 2018-11-13 2021-06-22 詹森生物科技公司 抗cd38抗体产生期间的痕量金属的控制
MA55284A (fr) * 2019-03-14 2022-01-19 Janssen Biotech Inc Procédés de production de compositions d'anticorps anti-tnf
CN114990049B (zh) * 2022-04-26 2024-01-16 鼎康(武汉)生物医药有限公司 一种同时调节细胞表达产物的糖型和电荷异质性的方法
CN116590371B (zh) * 2023-07-13 2023-10-17 智享生物(苏州)有限公司 一种降低中华仓鼠卵巢细胞中抗体高甘露糖型的细胞培养方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08336389A (ja) * 1995-06-14 1996-12-24 Mitsui Toatsu Chem Inc 糖蛋白質の糖鎖構造を制御する方法
ES2571230T3 (es) 1999-04-09 2016-05-24 Kyowa Hakko Kirin Co Ltd Procedimiento para controlar la actividad de una molécula inmunofuncional
US20030211573A1 (en) * 2000-02-08 2003-11-13 Thomas Ryll Galactosylation of recombinant glycoproteins
EP1417577A4 (en) 2001-08-14 2009-08-26 Verisity Design Inc SYSTEM AND METHOD FOR VCD ON DEMAND
US7439043B2 (en) 2001-10-10 2008-10-21 Neose Technologies, Inc. Galactosyl nucleotide sugars
WO2005070962A1 (en) 2004-01-21 2005-08-04 Novozymes A/S Production of a monoclonal antibody in a heterokaryon fungus or in a fungal host cell
CN1918179A (zh) * 2004-01-21 2007-02-21 诺和酶股份有限公司 在异核体真菌或真菌宿主细胞中产生单克隆抗体
AU2011205185B2 (en) * 2004-04-15 2013-05-09 Glycofi, Inc. Production of galactosylated glycoproteins in lower eukaryotes
AR058129A1 (es) 2005-10-21 2008-01-23 Genzyme Corp Productos terapeuticos basados en anticuerpos con actividad de adcc mejorada
EP2495308A1 (en) * 2005-12-08 2012-09-05 Amgen Inc. Improved production of glycoproteins using manganese
EP2108047B1 (en) * 2007-01-31 2012-10-24 Pfenex Inc. Bacterial leader sequences for increased expression
WO2010132341A2 (en) * 2009-05-11 2010-11-18 Pfenex, Inc. Production of recombinant proteins utilizing non-antibiotic selection methods and the incorporation of non-natural amino acids therein
NZ603883A (en) * 2010-05-27 2015-01-30 Merck Sharp & Dohme Method for preparing antibodies having improved properties
EP2678030A4 (en) * 2011-02-25 2015-02-18 Merck Sharp & Dohme PRODUCTION OF TNFRII-FC N- AND O-SIALYLATED HYBRID PROTEIN IN YEAST
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
KR20130057959A (ko) * 2011-11-24 2013-06-03 한화케미칼 주식회사 항 ｈｅｒ2 단일클론항체와 ｉｌ-2를 포함하는 융합 단일클론 항체 및 이를 포함하는 암치료용 조성물
EP2809773B1 (en) * 2012-01-30 2020-09-02 Dr. Reddy's Laboratories Limited Process of modulating man5 and/or afucosylation content of glycoprotein composition
KR101318498B1 (ko) 2012-03-08 2013-10-16 한화케미칼 주식회사 재조합 단백질의 생산성 향상을 위한 배양용 배지 첨가용 조성물
CN103320388B (zh) * 2012-03-20 2015-10-28 无锡药明康德生物技术股份有限公司 提高抗体表达量和改良糖基化水平的细胞培养方法

Also Published As

Publication number Publication date
WO2015152658A1 (ko) 2015-10-08
CN106459185B (zh) 2021-05-07
PT3127917T (pt) 2021-10-15
EP3127917A4 (en) 2017-04-26
CN106459185A (zh) 2017-02-22
ES2893536T3 (es) 2022-02-09
US10808272B2 (en) 2020-10-20
KR20150115066A (ko) 2015-10-14
EP3127917A1 (en) 2017-02-08
JP2017511137A (ja) 2017-04-20
KR101660580B1 (ko) 2016-09-28
EP3127917B1 (en) 2021-09-01
US20170107551A1 (en) 2017-04-20
JP6389530B2 (ja) 2018-09-12

Similar Documents

Publication Publication Date Title
IL285287B1 (en) Antibodies to tigit
KR102355950B9 (ko) Tigit에 대한 항체
DK3556775T3 (da) Anti-lag-3 antistoffer til behandling af hæmatologiske maligniteter
DK3192902T3 (da) Fremgangsmåde til fremstilling af graphenholdige viscosefibre
DK3183272T3 (da) Asymmetriske multispecifikke antistoffer
DK3140393T3 (da) Fremstillingsmetode for voksne leverstamceller
DK3556777T3 (da) Multispecifikke antistofkonstrukter
DK3126395T3 (da) Multispecifikke antistoffer
DK3191517T3 (da) Krydsreaktive siglec-antistoffer
DK3492632T3 (da) Metoder til behandling af lithiumholdige materialer
DK3164414T3 (da) Antistoffer for IL-15
CL2016001742A1 (es) Anticuerpos anti-baff novedosos
FI20146127A (fi) Prosessi hiilivetyjen valmistamiseksi
DK3253453T3 (da) Fremgangsmåde til fremstilling af mælk med højt indbygget vitamin D3-indhold
DK3166904T3 (da) Fremgangsmåde til fremstilling af betonelementer
DK3215517T3 (da) Ether-funktionaliseret lignin til brændstofsproduktion
DK3218396T3 (da) Fremgangsmåde til fremstilling af højaffinitets antistoffer
DK3160266T3 (da) Sukkererstatningssammensætning
IL247371A0 (en) Antibodies from individuals with increased stability
DK3138903T3 (da) Celler til produktion af humant antistof
DK3127917T3 (da) Fremgangsmåde til fremstilling af antistof gennem regulering af sukkerindhold i antistof
DK3286209T3 (da) Fremgangsmåde til fremstilling af gonadotrophin
DK3233915T3 (da) Antistoffer til il-17c
DK3347480T3 (da) Selvforsynende fremgangsmåde til fremstilling af biomassehydrolysat med reduceret saltindhold
FI20146104A (fi) Prosessi spirosyklisten substituoitujen bentsofurokinolitsiinien valmistamiseksi